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Summary
Background:  Completion  of  the  recommended  9-month  course  of  isoniazid  to  treat
latent  tuberculosis  infection  in  children  remains  poor  and  is  often  affected  by
adverse  effects,  including  hepatitis,  to  medication.  We  evaluated  the  frequency  of
isoniazid  therapy  completion  and  factors  associated  with  failure  to  complete  therapy
in  patients  aged  0—18  years.
Methods:  We  performed  a  retrospective  review  of  medical  records  for  patients  aged
0—18  years  who  were  referred  for  isoniazid  therapy  between  January  2005  and
August  2011  at  2  California  county  sites:  a  public  health  department  and  a  pedi-
atric  latent  tuberculosis  infection  clinic.  Medication  adherence  to  isoniazid  therapy
was  measured  by  monthly  pill  count.
Results:  There  were  1872  eligible  patients  who  were  referred  for  isoniazid  ther-
apy.  Of  the  1587  patients  who  met  inclusion  criteria  and  initiated  treatment,  1235
patients  (78%)  completed  the  9-month  therapy,  including  1046  of  1308  patients  aged
<15  years  (80%)  and  189  of  268  patients  aged  15—18  years  (71%).  Factors  that  were
signiﬁcantly  associated  with  failure  to  complete  therapy  included  age  15—18  years,
non-Hispanic  race,  development  of  hepatitis,  and  symptoms  of  adverse  effects.  The
association  between  age  and  the  development  of  hepatitis  was  similar  for  male  and
female  patients.
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Introduction
The  American  Thoracic  Society,  Centers  for  Disease
Control  and  Prevention,  and  Infectious  Diseases
Society of  America  guidelines,  endorsed  by  the
American  Academy  of  Pediatrics,  recommend  a
9-month course  of  isoniazid  to  treat  latent  tuber-
culosis infection  (LTBI)  in  children  and  adolescents
[1].  Young  children  have  a  greater  risk  of  progres-
sing to  active  tuberculosis  (TB),  and  children  have
more years  to  develop  TB  [2].  The  frequency  of
completion  of  a  9-month  isoniazid  course,  deﬁned
as 270  doses  taken  within  12  months,  is  low  in
children and  adolescents  (40.3—75%)  [3—5].  The
frequency of  completion  of  a  6-month  isoniazid  reg-
imen is  slightly  higher  in  some  studies  but  may
vary with  the  study  population  (Boston,  42.6%;  San
Diego, 74—86.7%  for  children  aged  <15  years)  [6—8].
Adverse effects  to  isoniazid  are  obstacles  to
completing isoniazid  therapy  [7,9,10].  Symptoms
that occur  during  LTBI  treatment  have  prevented
individuals from  completing  isoniazid  therapy
[11,12].  Cultural  and  ethnic  factors  may  affect
the acceptance  or  completion  of  isoniazid  ther-
apy [5—7,13,14].  However,  it  is  unknown  how  these
factors  contribute  to  the  adherence  to  isoniazid
therapy by  children.  The  purpose  of  the  present
study was  (1)  to  determine  the  adherence  to  9-
month isoniazid  therapy,  with  adherence  measured
objectively  by  monthly  pill  counts,  and  (2)  to  exam-
ine factors  associated  with  the  failure  to  complete
therapy in  patients  aged  0—18  years.  Part  of  the
study methods  in  this  paper  was  reported  in  a
previous  paper  (Chang  S,  Nahid  P,  Eitzman,  SR.
Hepatotoxicity  in  children  receiving  isoniazid  ther-
apy for  latent  tuberculosis  infection.  Unpublished
manuscript).
Materials and methods
Study settingIn this  retrospective  study,  we  reviewed  an  avail-
able  sample  of  patients  aged  0 to  18  years  who
were referred  to  either  of  2  sites  in  a  California
a
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lete  isoniazid  therapy  in  patients  aged  0—18  years  is
ispanic  race,  development  of  hepatitis,  and  symptoms
l  support  is  needed  for  adolescents  to  complete  therapy
ion.
ziz  University  for  Health  Sciences.  Published  by  Elsevier
ounty  (a public  health  department  and  a  pediatric
TBI clinic)  and  started  isoniazid  therapy  between
anuary 2005  and  August  2011.  The  study  was
pproved  by  the  Committee  on  Human  Research  at
niversity of  California,  San  Francisco  (IRB  #  11-
8230) and  the  institutional  review  board  at  Santa
lara Valley  Medical  Center  (IRB  #  11-059).  Patients
ho had  a  diagnosis  of  LTBI  were  included  if  they  (1)
ad a  positive  tuberculin  skin  test,  (2)  had  a  normal
hest radiograph,  and  (3)  were  prescribed  isoniazid
or 9 months.  Patients  were  excluded  if  they  (1)
ere already  receiving  isoniazid  therapy,  (2)  were
reviously  treated  and  resumed  isoniazid  therapy
ecause  of  interruption  in  treatment,  (3)  had  active
uberculosis,  (4)  were  treated  with  rifampin  ini-
ially rather  than  isoniazid,  or  (5)  had  inadequate
edical records  such  as  missing  monthly  pill  count.
reatment of latent tuberculosis infection
atients  aged  <2  years  were  referred  to  the  public
ealth  department  for  follow-up  through  comple-
ion  of  treatment.  The  medical  treatment  of  these
hildren  was  performed  by  their  primary  care  physi-
ian, with  public  health  nurses  who  followed  up
ith monthly  home  visits  to  assess  medication
dherence by  pill  count  and  to  monitor  for  adverse
ffects.
Patients aged  2—18  years  were  evaluated  and
ollowed at  the  pediatric  LTBI  clinic  by  a nurse
ractitioner. These  patients  had  a  complete  history,
hysical  examination,  and  assessment  of  medica-
ion adherence  by  pill  count  and  adverse  effects
efore receiving  each  1-month  reﬁll  of  medication.
f a  patient  had  ≥3-month  break  in  LTBI  ther-
py, the  patient  was  required  to  restart  treatment.
aseline serum  transaminase  tests  (before  starting
herapy)  were  performed  only  in  patients  who  were
t increased  risk  for  isoniazid-induced  hepatitis,
uch as  patients  who  received  combination  ther-
py (isoniazid  with  another  potentially  hepatotoxic
rug) or  patients  who  had  a  history  of  hepatitis  or
lcohol abuse.  In  patients  who  developed  hepatitis
uring treatment,  serum  transaminase  tests  were
epeated.  After  elevated  serum  transaminase  levels
ubsided, rifampin  therapy  was  offered  to  patients.
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ﬁactors  associated  with  failure  to  complete  isoniaz
hen  pregnancy  occurred,  isoniazid  was  discontin-
ed and  restarted  2—3  months  postpartum.  There
ere no  changes  in  this  treatment  protocol  at  the
ediatric  LTBI  clinic  from  2004  to  2012.
For children  who  were  lost  to  follow-up  or  failed
o keep  clinic  or  home  visits,  efforts  were  made  to
ontact  patients  by  telephone  or  letter.  There  was
o mechanism  to  track  completion  of  treatment  by
atients when  a  family  moved  out  of  the  county  or
ransferred  care  to  other  medical  providers  in  the
ommunity.
eﬁnitions and measures
ompletion  of  isoniazid  therapy  was  deﬁned  as
ompletion  of  270  planned  doses  during  a  9-month
eriod or  within  12  months  according  to  Ameri-
an Thoracic  Society,  Centers  for  Disease  Control
nd Prevention,  and  Infectious  Diseases  Society
f America  guidelines  [1].  Medication  adherence
as measured  by  monthly  pill  count  at  home  or
linic visits.  Adverse  effects  were  deﬁned  as  symp-
oms occurring  after  the  patient  started  therapy,
etermined from  a  checklist  of  symptoms  asso-
iated  with  adverse  effects  to  isoniazid  used  by
he public  health  nurses  and  the  LTBI  clinic  nurse
ractitioner. Symptoms  of  adverse  effects  that
ccurred  between  the  start  and  end  of  therapy
ere recorded  and  divided  by  the  number  of  actual
ome or  clinic  visits  to  obtain  a  rate  of  symptom
xperience over  time.
Hepatitis  was  deﬁned  as  elevation  of  serum
ransaminases  >  twice  the  upper  limit  of  normal
ULN) during  treatment.  The  researchers  had  a low
hreshold to  diagnose  hepatitis  because  the  pedi-
tric patients  were  difﬁcult  to  follow  and  were  less
ble to  describe  their  own  symptoms  than  adults;
herefore, if  the  patients  had  transaminase  levels
2 times  the  ULN,  the  patients  were  considered  to
ave early  hepatitis.
The parameters  that  were  assessed  as  possible
actors associated  with  failure  to  complete  therapy
ncluded  age,  sex,  race,  reason  for  referral  (TB  risk
lassiﬁcation),  induration  of  tuberculin  skin  test,
ymptoms  of  adverse  effect,  serum  transaminase
evels, reason  for  not  completing  treatment,  having
 family  member  receiving  treatment  for  tuber-
ulosis, clinic  location,  and  postal  zip  code.  The
utcome  measure  was  status  of  completion.
ample size and independencyample  size  was  estimated  by  multiple  logistic
egression analysis  (nQuery  Advisor,  version  4.0,
ork, Ireland).  It was  determined  that  a sample
ize of  1452  patients  would  be  needed  for  a  2-group
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hi-square  test  with  a 2-sided  signiﬁcance  level  of
05 and  80%  power  to  detect  a difference  between
roups having  85%  and  90%  frequency  of  comple-
ion (odds  ratio,  1.59).  When  >1  child  in  a family
as referred  for  evaluation  and  treatment,  only  the
oungest child  was  entered  as  a case.  The  names  of
arents were  used  to  identify  children  in  the  same
amily.
ata analysis
abulations  and  correlations  between  variables
ere performed  with  statistical  software  (SPSS,
ersion  20.0,  IBM  Corp.,  Armonk,  NY).  We  deter-
ined the  percentage  of  missing  data  for  each
ariable  of  interest,  and  variables  were  excluded
rom analysis  when  ≥20%  data  were  missing.  Sig-
iﬁcant predictors  were  identiﬁed  with  multiple
ogistic regression  analysis  based  on  P  ≤  .05.  There
as no  collinearity  among  predictors.  Examination
f the  patterns  of  data  showed  that  the  number
f cases  for  categorical  predictors  of  the  failure  to
omplete therapy  was  too  small,  and  the  assump-
ion of  a linear  relation  between  the  symptom  of
dverse effect  parameter  and  dependent  variable
as not  met.  To  address  these  problems,  we  used
he nonparametric  bootstrap  (SAS  version  9.1,  SAS,
ary, NC)  and  bias-corrected  conﬁdence  intervals
o identify  signiﬁcant  effects.  We  reported  the  odds
atio and  bias-corrected  95%  conﬁdence  interval  for
ach signiﬁcant  predictor  [15].  Signiﬁcant  effects
ere determined  on  the  basis  of  odds  ratio  not
qual to  1.  Exact  logistic  regression  (SAS  version
.1, SAS,  Cary,  NC)  was  used  to  evaluate  the  rela-
ion between  age  and  sex  on  the  development  of
epatitis.
esults
requency of completing isoniazid therapy
here  were  1872  patients  aged  0—18  years  who
ere referred  to  the  2  clinical  sites  for  a  diagno-
is of  LTBI  (Fig.  1).  There  were  174  patients  (9%)
ho did  not  start  isoniazid  therapy  including  47
atients  (27%)  who  transferred  care,  41  patients
24%) who  moved,  and  34  patients  (20%)  who  were
ost to  follow-up.  In  the  1673  remaining  patients
89%) who  started  therapy,  1587  patients  satis-
ed the  inclusion  criteria  (Fig.  1). Most  included
atients completed  9  months  of  isoniazid  ther-
py, and  the  frequency  of  therapy  completion  was
reater in  younger  than  older  patients  (P  ≤  .001)
Tables  1  and  2).  In  the  341  patients  who  did  not
148  S.-H.  Chang  et  al.
Chil dren referred wit h diagnosis of LTBI (n = 1847)
• Exc luded children, therapy no t started (n = 174 )
• Assessed for eligibilit y and started the rap y (n = 1673)
County Public Health Department (n = 56)
(age, 0 to 2  year s)
9 Excluded
• Inclusion criteria not met (n = 2)
2 received rifampin  regimen .
• Other reasons (n = 7)
6 had inadequ ate  records .
1 transferred to  the  LTBI clinic.
Reasons for inco mplete 9-mon th  iso niazid 
the rap y (n = 333)
• Completed < 9  mon ths isoniazid (n = 103)
• Tran sferr ed to  other provide r (n = 101)
• Moved or unab le  to foll ow up (n = 79)
• Los t to  follow -up (n = 21)
• Medical reasons  (n = 12)
6 developed hep atitis
2 had other reaction
4 pregnant
• Othe r reasons (n = 9)
• Refus ed  (n = 8)
Patien ts  treated only with  ison iazid  (n = 1540)
Reasons for inco mplete 9-mon th  iso niazid
the rap y (n = 8)
• Tran sferr ed to  other provide r (n = 1)
• Moved or unab le  to foll ow up (n = 4)
• Los t to  follow -up (n = 2)
• Medical reasons  (n = 1)
1 developed hep atitis
Patien ts  treated on ly with  ison iazid (n = 47)
LTBI Cli nic (n  = 1617)
(age, 2 to 18 year s)
77 Excluded
• Inclusion criteria not met (n = 5)
5 received rifampin  regimen .
• Othe r reasons (n = 72)
47 restarted the rap y be cause of incomplete 
the rapy previou sly or a break > 3 mon ths 
during therapy.
24 had ina dequate records .
1 discontinued iso niazid  becaus e of
documen ted completed  therapy.
Started  and treated with  isoniazid (n = 1587)
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TFigure  1  Flow  diagram  for  study  about  children  and  ado
complete  treatment,  208  patients  (61%)  transferred
care, moved,  or  were  lost  to  follow-up  (Fig.  1).
Most patients  who  started  therapy  were  aged
<15 years  and  Hispanic,  and  half  of  all  patients
who started  therapy  experienced  ≥1  symptom  of
adverse effects  (Table  1).  The  most  common  symp-
toms  of  adverse  effects  were  loss  of  appetite  or
abdominal  pain;  nausea,  vomiting,  or  diarrhea;  and
headache (Table  1).
Factors associated with failure to complete
treatmentSex,  reason  for  referral  (TB  risk  classiﬁcation),
induration  of  tuberculin  skin  test,  having  a fam-
ily member  receiving  treatment  for  tuberculosis,
s
n
p
yents  who  had  latent  tuberculosis  infection  (LTBI).
linic  location,  and  postal  zip  code  were  not
ssociated with  failure  to  complete  therapy  (uni-
ariate analysis)  and  were  excluded  from  further
nalysis.  In  multiple  logistic  regression,  factors
ndependently  associated  with  failure  to  complete
herapy  included  age  15—18  years,  non-Hispanic
ace, development  of  hepatitis,  and  symptoms  of
dverse effects  (Table  2).
actors associated with hepatitis
here  were  49  children  (3%)  who  had  elevated
erum transaminase  level  and  received  the  diag-
osis of  hepatitis  during  treatment  (Table  1).  Most
atients  who  developed  hepatitis  were  aged  <15
ears (Table  3). Exact  logistic  regression  showed
Factors  associated  with  failure  to  complete  isoniazid  th
Table  1  Demographic  and  clinical  characteristics
of  patients  who  started  isoniazid  therapy  for  latent
tuberculosis  infection.a
Characteristic  Number  (%)
Age  (years)  9  ±  5  (0.5—18)
<5  497  (31)
5—9  404  (26)
10—14 418  (26)
15—18 268  (17)
Sex
Female  794  (50)
Male  793  (50)
Raceb
Hispanic  1239  (79)
Asian  or  Paciﬁc  Islander  196  (12)
Other  73  (5)
Black  36  (2)
White  30  (2)
Reason  for  referralc
Positive  TST  1117  (86)
TST  conversion  within  24  months  88  (7)
Positive  TST  <  24  months  41  (3)
Other  reason  36  (3)
Close  contact  to  active  TB  case  13  (1)
TB  skin  test  induration  (mm)  14  ±  4  (5—50)
Adverse  effects
≥1  Adverse  effects  790  (50)
Loss  of  appetite  or  abdominal  pain  454  (29)
Nausea,  vomiting,  or  diarrhea 296  (19)
Headache  261  (16)
Rash  or  itching 74  (5)
Hepatitisd 49  (3)
Malaise  or  fatigue 45  (3)
Total  clinic  or  home  visits 8  ±  3  (0—14)
Family  members  on  treatment
Yes  157  (10)
No/unknown  1430  (90)
Completed  therapye
Yes  1235  (78)
No  341  (22)
a N = 1587 subjects. Data reported as number (%) or
mean ± SD (range, minimum to maximum). Abbreviations:
TB, tuberculosis; TST, tuberculin skin test.
b Data about race, available for 1574 patients (99%).
c Data about reasons for referral, available for 1295
patients (82%).
d Hepatitis deﬁned as serum transaminase level >2 times
the upper limit of normal.
e Completion data available for 1576 children (99%).
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more  likely  to  complete  therapy  than  non-Hispanichat  age  and  sex  were  not  associated  with  the
evelopment of  hepatitis,  and  the  effect  of  age  on
he development  of  hepatitis  did  not  differ  by  sex
Table  3).
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iscussion
he  present  results  showed  a  high  frequency  of
ompleting  a 9-month  course  of  isoniazid  ther-
py (78%),  greater  in  patients  aged  <15  years
Tables  1 and  2). The  frequency  of  therapy  com-
letion  in  patients  aged  <15  years  was  greater
han that  reported  in  a previous  study  from  Colum-
us, Ohio  in  which  54.4%  patients  aged  <15  years
ompleted  therapy  [5]. The  present  frequency  of
ompleting  therapy  for  all  patients  aged  <18  years
78%) was  similar  to  that  reported  in  a  previous
tudy from  Houston,  Texas  (76%)  [3].
In studies  that  deﬁne  therapy  completion  as
 months  of  isoniazid  therapy,  the  frequency  of
herapy  completion  in  patients  aged  <15  years  is
4—86.7% [6,7].  In  the  present  study,  1138  of  1319
atients  (86%)  completed  6  months  of  isoniazid,
imilar to  a  previous  study  of  a predominantly
ispanic  population  in  San  Diego  (86.7%)  [6].  In
he Houston  study,  the  directly  observed  ther-
py method  used  in  half  of  the  patients  may
ave contributed  to  a  higher  frequency  of  com-
letion [3]. In  the  San  Diego  study,  many  patients
eceived behavioral  intervention  (47%)  and  source
ase investigation  (36%)  [6]. In  the  present  study,
nly 3 children  received  directly  observed  therapy,
nd all  others  had  self-administered  therapy.
Several  factors  may  have  contributed  to  the  high
requency  of  therapy  completion  in  the  present
tudy. Pill  counts  by  the  nurse  practitioner  might
ncrease  parental  diligence,  increasing  children’s
edication  adherence.  In  addition,  follow-up
fforts included  telephone  calls  and  letters  to
emind  patients  of  their  appointments  and  retrieve
atients  lost  to  follow-up.  Furthermore,  medical
are was  accessible,  with  5  LTBI  clinic  locations
n the  county  for  families  in  different  geographic
reas, and  this  may  have  increased  the  frequency
f therapy  completion  over  other  settings  in  which
uberculosis  care  may  be  centralized.
In the  present  study,  age  15—18  years,  non-
ispanic race,  hepatitis,  and  symptoms  of  adverse
ffects  were  independently  associated  with  fail-
re to  complete  isoniazid  therapy  (Table  2). These
ndings  are  consistent  with  those  of  other  studies
hat showed  that  older  age  (15—18  years)  is  a fac-
or in  failure  to  complete  therapy  [7,13,16—18].
ounger children  may  be  more  likely  than  ado-
escents or adults  to  complete  isoniazid  therapy
ecause of  more  intense  parental  supervision  in
ounger patients.
The present  ﬁnding  that  Hispanic  patients  wereatients (Table  2) also  is consistent  with  previous
eports [6,7]. There  may  be  greater  openness  to
150  S.-H.  Chang  et  al.
Table  2  Factors  associated  with  failure  to  complete  isoniazid  therapy  for  latent  tuberculosis  infection.a
Characteristic  Completed  Not  completed  Total  Bootstrap  analysis,
odds  ratio  (95%
conﬁdence  interval)
No.  subjects  (%)  1235  (78)  341  (22)  1576  (100)
Age  (years)
0  to  <5 394  (81) 93  (19) 487  (31)  Reference  (1.0)
5  to  <10 321  (80) 82  (20) 403  (26) 1.2  (0.8—1.8)
10  to  <15 331  (79) 87  (21) 418  (27) 1.3  (1.0—1.9)
≥15—18 189  (71) 79  (29) 268  (17) 2.0  (1.3—3.0)b
Racec
Non-Hispanic  235  (71) 95  (29) 330  (21) 1.8  (1.3—2.4)b
Hispanic  989  (80)  244  (20)  1233  (79)  Reference  (1.0)
Hepatitisd
No  1228  (80)  299  (20)  1527  (97)  Reference  (1.0)
Yes  7  (14)  42  (86)  49  (3)  24.6  (10.5—62.8)b
Symptoms  of
adverse  effectse
0.2  ±  0.2  (0—1.2)  0.2  ±  0.4  (0—3.0)  0.2  ±  0.3  (0—3.0)  2.0  (1.2—3.0)b
a N = 1587 subjects who started therapy; completion data available for 1576 subjects (99%). Data reported as number (%) or
mean ± SD (range, minimum to maximum).
b Signiﬁcant effect by odds ratio and 95% conﬁdence interval.
c Data about race, available for 1563 patients.
e upp
effec
a
c
o
td Hepatitis deﬁned as serum transaminase level >2 times th
e Symptoms of adverse effects = total symptoms of adverse 
LTBI  therapy  in  parents  from  Central  or  South  Amer-
ica than  parents  from  Eastern  Europe  or  Asia  [5].
We conﬁrmed  that  symptoms  associated  with
adverse effects  of  isoniazid  are  an  obstacle  to
completing  therapy  (Table  2) [7,9,10].  Symptoms
such as  abdominal  pain  or  loss  of  appetite  may
occur with  many  minor  illnesses,  but  patients  may
(
p
m
Table  3  Factors  associated  with  hepatitis  in  patients  w
infection.a
Characteristic  No  hepatitis  He
0—14
years
15—18
years
Total  0—
ye
Agec 1281  (83)  257  (17)  1538  38
Sexc
Female  652  (85) 117  (15)  769  17
Male  629  (82)  140  (18)  769  21
a N = 1587 subjects who started therapy. Data reported as numbe
b NS, not signiﬁcant (P > .05).
c Interaction of age with sex: adjusted odds ratio, 4.0 (95% conﬁ
d Reference group, age 0—14 years.er limit of normal.
ts divided by total clinic or home visits during treatment.
ssociate  such  symptoms  with  isoniazid  and  dis-
ontinue  therapy.  Hepatitis,  deﬁned  by  elevation
f serum  transaminase  >2  times  ULN,  was  a  fac-
or associated  with  failure  to  complete  therapy
Table  2),  possibly  because  of  the  decision  of  the
rovider  or  patient.  Patients  who  have  hepatitis
ay require  more  frequent  blood  tests  and  may
ho  started  isoniazid  therapy  for  latent  tuberculosis
patitis  Exact  logistic
regression,
adjusted  odds
ratio  (95%
conﬁdence
interval),  P≤b
14
ars
15—18
years
Total
 (78)  11  (22)  49  0.6d (0.1—2.2)
NS
 (68)  8  (32)  25  0.8  (0.4—1.6)
NS
 (88)  3  (13)  24  Reference
(1.0)
r (%) or number of subjects.
dence interval, 0.8—28), not signiﬁcant.
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vactors  associated  with  failure  to  complete  isoniaz
iscontinue  therapy  because  they  may  be  reluc-
ant to  allow  additional  venipunctures  [19]  or  may
e concerned  about  drug  safety.  Further  study  is
eeded to  evaluate  the  perceptions  of  children  and
arents  about  the  adverse  effects  of  drugs  and
lood tests  required  to  treat  hepatitis.
Although there  was  no  signiﬁcant  interaction
ffect between  age  and  sex  on  the  development
f hepatitis  (Table  3),  a  true  effect  might  not
ave been  evident  because  of  insufﬁcient  statis-
ical power.  There  is  little  information  available
bout the  effect  of  the  interaction  of  age  and  sex
n the  development  of  hepatitis,  and  the  effect  of
ge on  the  development  of  hepatitis  might  differ
etween  females  and  males  aged  <18  years.  Future
tudies  with  larger  sample  sizes  are  necessary  to
valuate  the  interaction  between  age  and  sex  on
he development  of  hepatitis.
The present  study  had  several  limitations.  We
sed a  convenience  sample  of  patients  with  medi-
al records  from  a  single  county.  The  sample  was
rimarily from  a  specialty  clinic  in  which  many
ispanic children  with  public  medical  insurance
ere treated.  Larger  samples  of  ethnically  diverse
opulations  may  be  useful  because  ethnicity  and
ocioeconomic  status  may  be  confounding  variables
or treatment  adherence.  In  addition,  the  use  of
ill counts  to  quantify  compliance  may  overesti-
ate compliance  in  children  who  remove  pills  from
ottles before  the  pill  count.  Another  potential
roblem of  using  pill  counts  to  determine  com-
liance with  drug  therapy  is that  the  outcome  of
herapy  completion  may  have  been  biased  by  the
esponse  of  parents  to  pill  counts  and  the  increased
ikelihood of  adherence  in  the  younger  children
upervised by  a  parent.  Biomarker  devices  may  gen-
rate accurate  results  and  may  be  used  to  monitor
dherence, such  as  urine  strips  [20,21]  or  medi-
ation  event  monitoring  systems  that  record  the
ate and  time  when  bottle  caps  are  opened  [22],
ut these  devices  may  be  costly.  Furthermore,  data
bout the  frequency  of  therapy  completion  were
navailable  for  208  children  who  transferred  care,
oved,  or  were  lost  to  follow-up  (Fig.  1);  these
atients were  included  in  the  group  that  failed
o complete  therapy,  and  this  may  have  caused
n underestimation  of  the  frequency  of  therapy
ompletion for  patients  who  may  have  completed
herapy elsewhere.  Similarly,  for  children  who  were
ost to  follow-up  and  who  did  not  start  therapy,  we
ad no  data  about  the  reasons  for  not  accepting
soniazid therapy.The Pediatric  Tuberculosis  Collaborative  Group
ecommended 3  types  of  intervention  for  promoting
dherence to  treatment  of  LTBI  in  children  and  ado-
escents:  educational,  organizational/support,  and
H
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ehavioral  [2]. In  the  present  study,  our  clinic  pro-
ided organization  support,  with  5  convenient  clinic
ites, accessible  open  hours,  and  language  capac-
ty to  communicate  with  Spanish-speaking  patients.
hese provisions  supported  children  and  their  par-
nts in  accessing  and  completing  LTBI  therapy  in  a
ounty with  a high  frequency  of  tuberculosis  [23].
owever, additional  investment  in  education  and
ehavioral  support  for  LTBI  therapy  is  advised  and
ay help  address  some  of  the  risk  factors  identiﬁed
or failure  to  complete  therapy.  The  diagnosis  and
reatment  of  LTBI  are  important  in  the  efforts  to
liminate tuberculosis.
onclusions
ailure  to  complete  isoniazid  therapy  in  patients
ged 0—18  years  was  affected  by  older  age,
on-Hispanic race,  development  of  hepatitis,  and
ymptoms  of  adverse  effects  (Table  2).  The  present
ndings  suggest  that  additional  support  is  needed
or adolescents  to  complete  LTBI  therapy.  Addi-
ional studies  may  focus  on  factors  that  affect  the
dherence  of  adolescents  to  LTBI  therapy.  More
tudies  are  needed  to  conﬁrm  that  adolescent
emales may  be  at  greater  risk  of  developing  hep-
titis than  adolescent  males.
unding
one.
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